Cancer drug olaparib may cause folate deficiency, small study finds
NCT ID NCT04024254
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study checked if the cancer drug olaparib causes low folate (folic acid) levels in the blood. Ten women with advanced ovarian or breast cancer participated. Researchers measured folate levels and looked for related drops in hemoglobin. The goal was to understand side effects of the drug.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Rush University Medical Center
Chicago, Illinois, 60612, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a radioactive tracer pinpoint Cancer's first stop?
- Can a personalized exercise program boost recovery in cancer survivors?
- Smartwatch could spot nerve damage before it starts
- Could ionized gas help fight breast cancer after surgery?
- Radiation may let breast cancer patients keep their nipple
- Can a new drug combo revive Immunotherapy's power against resistant tumors?